Logo for Sprint Bioscience

Sprint Bioscience Investor Relations Material

Latest events

Logo for Sprint Bioscience

Q4 2023

14 Feb, 2024
Logo for Sprint Bioscience

Q3 2023

25 Oct, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Sprint Bioscience

Access all reports
Sprint Bioscience AB engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB was founded in 2009 and is based in Huddinge, Sweden.